Abstract
We have investigated the existence, molecular composition, and benzodiazepine binding properties of native cortical alpha1-alpha3 gamma-aminobutyric acidA (GABAA) receptors using subunit-specific antibodies. The co-existence of alpha1 and alpha3 subunits in native GABAA receptors was demonstrated by immunoblot analysis of the anti-alpha1- or anti-alpha3-immunopurified receptors and by immunoprecipitation experiments of the [3H]zolpidem binding activity. Furthermore, immunodepletion experiments indicated that the alpha1-alpha3 GABAA receptors represented 54.7 +/- 5.0 and 23.6 +/- 3.3% of the alpha3 and alpha1 populations, respectively. Therefore, alpha1 and alpha3 subunits are associated in the same native GABAA receptor complex, but, on the other hand, these alpha1-alpha3 GABAA receptors from the cortex constitute a large proportion of the total alpha3 population and a relatively minor component of the alpha1 population. The pharmacological analysis of the alpha1- or alpha3-immunopurified receptors demonstrated the presence of two different benzodiazepine binding sites in each receptor population with high (type I binding sites) and low (type II binding sites) affinities for zolpidem and Cl 218,872. These results indicate the existence of native GABAA receptors possessing both alpha1 and alpha3 subunits, with alpha1 and alpha3 subunits expressing their characteristic benzodiazepine pharmacology. The molecular characterization of the anti-alpha1-anti-alpha3 double-immunopurified receptors demonstrated the presence of stoichiometric amounts of alpha1 and alpha3 subunits, associated with beta2/3, and gamma2 subunits. The pharmacological analysis of alpha1-alpha3 GABAA receptors demonstrated that, despite the fact that each alpha subunit retained its benzodiazepine binding properties, the relative proportion between type I and II binding sites or between 51- and 59-61-kDa [3H]Ro15-4513-photolabeled peptides was 70:30. Therefore, the alpha1 subunit is pharmacologically predominant over the alpha3 subunit. These results indicate the existence of active and nonactive alpha subunits in the native alpha1-alpha3 GABAA receptors from rat cortex.
Highlights
The co-existence of ␣1 and ␣3 subunits in native GABAA receptors was demonstrated by immunoblot analysis of the anti-␣1- or anti-␣3-immunopurified receptors and by immunoprecipitation experiments of the [3H]zolpidem binding activity
␣1 and ␣3 subunits are associated in the same native GABAA receptor complex, but, on the other hand, these ␣1-␣3 GABAA receptors from the cortex constitute a large proportion of the total ␣3 population and a relatively minor component of the ␣1 population
Neither anti-␣3 nor anti-␣1 antisera immunoreacted with peptides from similar regions of other ␣ subunits (Fig. 1A). 2) The immunoprecipitation of the native receptors was inhibited by the peptide used as antigen but not by others corresponding to similar NH3ϩ- or COOϪ-terminal regions of other ␣ subunits (Fig. 1, B and C). 3) In immunoblots using the affinity-purified GABAA receptor (Fig. 1D) anti-␣3 antiserum immunoreacted with a faint band of Mr 59,000 (␣3 subunit), whereas anti-␣1 strongly reacted with a single band of Mr 51,000 (␣1 subunit)
Summary
The co-existence of ␣1 and ␣3 subunits in native GABAA receptors was demonstrated by immunoblot analysis of the anti-␣1- or anti-␣3-immunopurified receptors and by immunoprecipitation experiments of the [3H]zolpidem binding activity. The pharmacological analysis of the ␣1- or ␣3-immunopurified receptors demonstrated the presence of two different benzodiazepine binding sites in each receptor population with high (type I binding sites) and low (type II binding sites) affinities for zolpidem and Cl 218,872 These results indicate the existence of native GABAA receptors possessing both ␣1 and ␣3 subunits, with ␣1 and ␣3 subunits expressing their characteristic benzodiazepine pharmacology. The presence of different ␣ subunits determines the affinity of the different benzodiazepine binding sites In this sense, the ␣1-1–3-␥2 combination confers type I pharmacology to the recombinant GABAA receptor (i.e. high affinity for, among others, zolpidem and Cl 218,872) [11]. Type II properties are conferred by the presence of ␣2, ␣3, or ␣5 subunits [11, 12]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
